These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 28781202)

  • 1. Biomarkers for cognitive dysfunction in Parkinson's disease.
    Kalia LV
    Parkinsonism Relat Disord; 2018 Jan; 46 Suppl 1():S19-S23. PubMed ID: 28781202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarkers of cognitive decline in Parkinson's disease.
    Lin CH; Wu RM
    Parkinsonism Relat Disord; 2015 May; 21(5):431-43. PubMed ID: 25737398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Markers of cognitive decline in PD: The case for heterogeneity.
    Monchi O; Hanganu A; Bellec P
    Parkinsonism Relat Disord; 2016 Mar; 24():8-14. PubMed ID: 26774536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal Fluid Biomarkers of Cognitive Decline in Parkinson's Disease.
    Johar I; Mollenhauer B; Aarsland D
    Int Rev Neurobiol; 2017; 132():275-294. PubMed ID: 28554411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional brain imaging of cognitive dysfunction in Parkinson's disease.
    Hirano S; Shinotoh H; Eidelberg D
    J Neurol Neurosurg Psychiatry; 2012 Oct; 83(10):963-9. PubMed ID: 22807560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarkers for dementia and mild cognitive impairment in Parkinson's disease.
    Delgado-Alvarado M; Gago B; Navalpotro-Gomez I; Jiménez-Urbieta H; Rodriguez-Oroz MC
    Mov Disord; 2016 Jun; 31(6):861-81. PubMed ID: 27193487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Grey matter atrophy in cognitively impaired Parkinson's disease.
    Melzer TR; Watts R; MacAskill MR; Pitcher TL; Livingston L; Keenan RJ; Dalrymple-Alford JC; Anderson TJ
    J Neurol Neurosurg Psychiatry; 2012 Feb; 83(2):188-94. PubMed ID: 21890574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroimaging correlates of cognitive impairment and dementia in Parkinson's disease.
    Mak E; Su L; Williams GB; O'Brien JT
    Parkinsonism Relat Disord; 2015 Aug; 21(8):862-70. PubMed ID: 26004683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-Sectional and Longitudinal Cognitive Correlates of FDDNP PET and CSF Amyloid-β and Tau in Parkinson's Disease1.
    Buongiorno M; Antonelli F; Compta Y; Fernandez Y; Pavia J; Lomeña F; Ríos J; Ramírez I; García JR; Soler M; Cámara A; Fernández M; Basora M; Salazar F; Sanchez-Etayo G; Valldeoriola F; Barrio JR; Marti MJ
    J Alzheimers Dis; 2017; 55(3):1261-1272. PubMed ID: 27814297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcortical shape analysis of progressive mild cognitive impairment in Parkinson's disease.
    Chung SJ; Shin JH; Cho KH; Lee Y; Sohn YH; Seong JK; Lee PH
    Mov Disord; 2017 Oct; 32(10):1447-1456. PubMed ID: 28737237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The neurobiological basis of cognitive impairment in Parkinson's disease.
    Halliday GM; Leverenz JB; Schneider JS; Adler CH
    Mov Disord; 2014 Apr; 29(5):634-50. PubMed ID: 24757112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cognitive impairment in degenerative parkinsonisms: role of radionuclide brain imaging.
    Arnaldi D; Morbelli S; Morrone E; Campus C; Nobili F
    Q J Nucl Med Mol Imaging; 2012 Feb; 56(1):55-67. PubMed ID: 22460160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gray matter atrophy associated with mild cognitive impairment in Parkinson's disease.
    Chen FX; Kang DZ; Chen FY; Liu Y; Wu G; Li X; Yu LH; Lin YX; Lin ZY
    Neurosci Lett; 2016 Mar; 617():160-5. PubMed ID: 26742642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease.
    Stav AL; Aarsland D; Johansen KK; Hessen E; Auning E; Fladby T
    Parkinsonism Relat Disord; 2015 Jul; 21(7):758-64. PubMed ID: 25971633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered functional connectivity in the default mode network is associated with cognitive impairment and brain anatomical changes in Parkinson's disease.
    Lucas-Jiménez O; Ojeda N; Peña J; Díez-Cirarda M; Cabrera-Zubizarreta A; Gómez-Esteban JC; Gómez-Beldarrain MÁ; Ibarretxe-Bilbao N
    Parkinsonism Relat Disord; 2016 Dec; 33():58-64. PubMed ID: 27659747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease.
    Skogseth RE; Bronnick K; Pereira JB; Mollenhauer B; Weintraub D; Fladby T; Aarsland D
    J Parkinsons Dis; 2015; 5(4):783-92. PubMed ID: 26599300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in the treatment of cognitive impairment in Parkinson's disease.
    Goldman JG; Weintraub D
    Mov Disord; 2015 Sep; 30(11):1471-89. PubMed ID: 26297863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Mild cognitive impairment in Parkinson's disease].
    Wada K; Nakashima K
    Brain Nerve; 2012 Dec; 64(12):1365-75. PubMed ID: 23209063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cognitive impairment in early-stage non-demented Parkinson's disease patients.
    Pfeiffer HC; Løkkegaard A; Zoetmulder M; Friberg L; Werdelin L
    Acta Neurol Scand; 2014 May; 129(5):307-18. PubMed ID: 24117192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prefrontal dopamine signaling and cognitive symptoms of Parkinson's disease.
    Narayanan NS; Rodnitzky RL; Uc EY
    Rev Neurosci; 2013; 24(3):267-78. PubMed ID: 23729617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.